66 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Fluorinated Chaperone-ß-Cyclodextrin Formulations forß-Glucocerebrosidase Activity Enhancement in Neuronopathic Gaucher Disease.
University of Sevilla
Inhibitor versus chaperone behaviour of d-fagomine, DAB and LAB sp(2)-iminosugar conjugates against glycosidases: A structure-activity relationship study in Gaucher fibroblasts.
University of Seville
Design and Synthesis of Potent Quinazolines as Selectiveß-Glucocerebrosidase Modulators.
Northwestern University Feinberg School of Medicine
Conformationally-locked N-glycosides: exploiting long-range non-glycone interactions in the design of pharmacological chaperones for Gaucher disease.
Universitat Rovira I Virgili
Identification and development of biphenyl substituted iminosugars as improved dual glucosylceramide synthase/neutral glucosylceramidase inhibitors.
Leiden University
Concise synthesis of C-1-cyano-iminosugars via a new Staudinger/aza Wittig/Strecker multicomponent reaction strategy.
Technical University Graz
Docking and SAR studies of calystegines: binding orientation and influence on pharmacological chaperone effects for Gaucher's disease.
University of Toyama
Rapid modifications of N-substitution in iminosugars: development of newß-glucocerebrosidase inhibitors and pharmacological chaperones for Gaucher disease.
Genomics Research Center
Rational design and synthesis of highly potent pharmacological chaperones for treatment of N370S mutant Gaucher disease.
Peking University
a-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based orala-glucosidase inhibitor for improving postprandial hyperglycemia.
University of Toyama
Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase.
National Center For Advancing Translation Sciences
Conformationally-locked N-glycosides with selectiveß-glucosidase inhibitory activity: identification of a new non-iminosugar-type pharmacological chaperone for Gaucher disease.
Universitat Rovira I Virgili
Potent aminocyclitol glucocerebrosidase inhibitors are subnanomolar pharmacological chaperones for treating gaucher disease.
Institut De Qu£Mica Avan£Ada De Catalunya (Iqac-Csic)
Rapid assembly of a library of lipophilic iminosugars via the thiol-ene reaction yields promising pharmacological chaperones for the treatment of Gaucher disease.
University of British Columbia
The myo-1,2-Diaminocyclitol Scaffold Defines Potent Glucocerebrosidase Activators and Promising Pharmacological Chaperones for Gaucher Disease.
TBA
Click chemistry approach to new N-substituted aminocyclitols as potential pharmacological chaperones for Gaucher disease.
Universitat De Barcelona
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
Hokuriku University
Novel alpha-glucosidase inhibitors with a tetrachlorophthalimide skeleton.
University of Tokyo
Homoisofagomines: chemical-enzymatic synthesis and evaluation as alpha- and beta-glucosidase inhibitors.
Technische Universit£T Berlin
A new strong inhibitor of beta-mannosidase.
S.E.S.N.A.B., Pole Sciences Et Technologie, Universit�
Potent glycosidase inhibitors, N-phenyl cyclic isourea derivatives of 5-amino- and 5-amino-1-C-(hydroxymethyl)-cyclopentane-1,2,3,4-tetraols
TBA
The Interaction of Anhydroalditols with Sweet-Almond -glucosidase and Escherichia coli -galactosidase: implications for the design of potent glycosidase inhibitors
TBA
Synthesis and glycosidase inhibitory profiles of functionalised morpholines and oxazepanes.
University of Reading
Docking and SAR studies of D- and L-isofagomine isomers as humanß-glucocerebrosidase inhibitors.
University of Toyama
New glucocerebrosidase inhibitors by exploration of chemical diversity of N-substituted aminocyclitols using click chemistry and in situ screening.
Spanish National Research Council (Consejo Superior De Investigaciones Cienti£?Ficas)
Synthesis of N-alkylated noeurostegines and evaluation of their potential as treatment for Gaucher's disease.
Aarhus University
Identification of Potent and Selective Glucosylceramide Synthase Inhibitors from a Library of N-Alkylated Iminosugars
TBA
Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.
Harvard Medical School
Synthesis of new beta-1-C-alkylated imino-L-iditols: A comparative study of their activity as beta-glucocerebrosidase inhibitors.
Orleans University
Nanomolar affinity, iminosugar-based chemical probes for specific labeling of lysosomal glucocerebrosidase.
Utrecht University
Synthesis and biological activity of C-6 modified derivatives of the glucosidase inhibitor 1-deoxynojirimycin.
TBA
Glycosidase-inhibiting pyrrolidines and pyrrolizidines with a long side chain in Scilla peruviana.
Hokuriku University
Identification of novel glucocerebrosidase chaperones by unexpected skeletal rearrangement reaction.
Eisai
Identification of pyrimidinyl piperazines as non-iminosugar glucocerebrosidase (GCase) pharmacological chaperones.
Eisai
trans, trans-2-C-Aryl-3,4-dihydroxypyrrolidines as potent and selective β-glucosidase inhibitors: Pharmacological chaperones for Gaucher disease.
Chinese Academy of Sciences
Discovery of Brain-Penetrant Glucosylceramide Synthase Inhibitors with a Novel Pharmacophore.
Takeda Pharmaceutical
Synthesis of multimeric pyrrolidine iminosugar inhibitors of human β-glucocerebrosidase and α-galactosidase A: First example of a multivalent enzyme activity enhancer for Fabry disease.
Universidad De Sevilla
Powerful probes for glycosidases: novel, fluorescently tagged glycosidase inhibitors.
Institut FüR Biochemie Der Technischen UniversitäT Graz
Novel, lipophilic derivatives of 2,5-dideoxy-2,5-imino-D-mannitol (DMDP) are powerful beta-glucosidase inhibitors.
Technische UniversitäT Graz
Novel compounds that reverse the disease phenotype in Type 2 Gaucher disease patient-derived cells.
Temple University
Conversion of Quinazoline Modulators from Inhibitors to Activators of β-Glucocerebrosidase.
Northwestern University
Exploring the effect of chirality on the therapeutic potential of N-alkyl-deoxyiminosugars: anti-inflammatory response to Pseudomonas aeruginosa infections for application in CF lung disease.
University of Napoli Federico Ii
Tuning of β-glucosidase and α-galactosidase inhibition by generation and in situ screening of a library of pyrrolidine-triazole hybrid molecules.
University of Seville
N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer ofα-Glucosidase Activity for the Treatment of Pompe Disease.
University of Naples Federico II
Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity
Northwestern University
Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity
Northwestern University
Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidase
Amicus Therapeutics
Activity based probes (ABPs) interacting with glycosidases
Academisch Medisch Centrum Bij Universiteit Van Amsterdam
Compositions for preventing and/or treating degenerative disorders of the central nervous system
Amicus Therapeutics
New insights into the pharmacological chaperone activity of c2-substituted glucoimidazoles for the treatment of Gaucher disease.
Nankai University
Synthesis, kinetic evaluation and cell-based analysis of C-alkylated isofagomines as chaperones of β-glucocerebrosidase.
University of British Columbia
Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry.
Research Institute, Hospital For Sick Children
Ultrasensitive in situ visualization of active glucocerebrosidase molecules.
Leiden University
N(4)-Phenyl modifications of N(2)-(2-hydroxyl)ethyl-6-(pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamines enhance glucocerebrosidase inhibition by small molecules with potential as chemical chaperones for Gaucher disease.
Nih
Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease.
Nih
Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention.
The Scripps Research Institute